Ontology highlight
ABSTRACT: Background
Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. Although new triple therapy (pegylated-interferon, ribavirin, and telaprevir/boceprevir) has recently been started and is expected to achieve a sustained virologic response of more than 70% in HCV genotype 1 patients, there are several problems to be resolved, including skin rash/ageusia and advanced anemia. Thus a new type of anti-HCV drug is still needed.Methodology/principal findings
Recently developed HCV drug assay systems using HCV-RNA-replicating cells (e.g., HuH-7-derived OR6 and Li23-derived ORL8) were used to evaluate the anti-HCV activity of drug candidates. During the course of the evaluation of anti-HCV candidates, we unexpectedly found that two preclinical antimalarial drugs (N-89 and its derivative N-251) showed potent anti-HCV activities at tens of nanomolar concentrations irrespective of the cell lines and HCV strains of genotype 1b. We confirmed that replication of authentic HCV-RNA was inhibited by these drugs. Interestingly, however, this anti-HCV activity did not work for JFH-1 strain of genotype 2a. We demonstrated that HCV-RNA-replicating cells were cured by treatment with only N-89. A comparative time course assay using N-89 and interferon-? demonstrated that N-89-treated ORL8 cells had more rapid anti-HCV kinetics than did interferon-?-treated cells. This anti-HCV activity was largely canceled by vitamin E. In combination with interferon-? and/or ribavirin, N-89 or N-251 exhibited a synergistic inhibitory effect.Conclusions/significance
We found that the preclinical antimalarial drugs N-89 and N-251 exhibited very fast and potent anti-HCV activities using cell-based HCV-RNA-replication assay systems. N-89 and N-251 may be useful as a new type of anti-HCV reagents when used singly or in combination with interferon and/or ribavirin.
SUBMITTER: Ueda Y
PROVIDER: S-EPMC3758303 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature
Ueda Youki Y Takeda Midori M Mori Kyoko K Dansako Hiromichi H Wakita Takaji T Kim Hye-Sook HS Sato Akira A Wataya Yusuke Y Ikeda Masanori M Kato Nobuyuki N
PloS one 20130830 8
<h4>Background</h4>Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. Although new triple therapy (pegylated-interferon, ribavirin, and telaprevir/boceprevir) has recently been started and is expected to achieve a sustained virologic response of more than 70% in HCV genotype 1 patients, there are several problems to be resolved, including skin rash/ageusia and advanced anemia. Thus a new type of anti-HCV drug is still needed.<h4>Methodology ...[more]